A phase I safety and feasibility study of Cytori Cell Therapy as a novel thermal burn countermeasure.
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs ECCS 50 (Primary)
- Indications Burns
- Focus Adverse reactions
- Acronyms RELIEF
- 10 Aug 2017 According to a Cytori Therapeutics media release, enrollment in this trial is expected to begin in Q4 2017.
- 10 Apr 2017 According to a Cytori Therapeutics media release, the company has that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for a pilot clinical trial to evaluate Cytori Cell Therapy in patients with thermal burn injury.
- 23 Mar 2017 According to a Cytori Therapeutics media release, company anticipates receiving feedback from U.S. FDA regarding thermal burn IDE trial application in Q2 2017.